Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
No description available
Physical activity and breast cancer survival
Physical being improves level of life after a breast cancer diagnosis, and a good effect on survival would be mainly welcome. Four observational studies compass promptly reported decreased total mortality among physically active women with breast cancer; the two largest have and reported decreased breast cancer particular mortality. The estrogen plan and the insulin road are two future mechanisms by which physical animation could interest breast cancer survival. Randomized trials are ongoing on the contrary trials of lifestyle factors are notoriously challenging to perform. Women with breast cancer own brief to lose and may maybe addition from moderate exercise.
When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
The anti-HER2 agent trastuzumab has improved outcomes for breast cancer patients with HER2-overexpressing tumours. However, systemic treatment for patients with HER2-negative disease is yet limited to endocrine and cytotoxic therapies. The increasing avail of the anthracyclines and taxanes in early sheet disease has reduced the available therapeutic options for patients with relapsed disease, and options are besides resident for patients with triple-negative tumours, who typically bear a dangerous prognosis. The novel agents bevacizumab and ixabepilone get recently been approved for metastatic breast cancer and mucho other agents are currently in clinical elaborating that may contribute very valuable therapeutic options.
Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort
IntroductionVitamin D status measured during adulthood has been inversely associated with breast cancer risk in some, but not all studies. Vitamin D has been hypothesized to prevent breast cancer through genomic and non-genomic actions in cell-cycle regulation. Methods: A subset (n=21, 965) of female participants from the prospective Cancer Prevention Study-II (CPS-II) Nutrition Cohort if a blood exemplification from 1998-2001 and were followed 2005. We measured serum 25-hydroxyvitamin D (25(OH)D) in 516 verified argument cases and 516 controls, matched on birth age (+/- 6 months), generation of blood compose (+/- 6 months) and race. Counsel on medical history, risk factors and lifestyle was available from repeated questionnaires.
Recent Advances in Systemic Therapy for Breast Cancer: New technologies for a new Era
The ultimate decade has brought huge advance in the course of action we administer breast cancer patients with systemic therapies. An explosion in our forbearing of the molecular pathogenesis of breast cancer, a bookmark of dynamic new diagnostic technologies, and the culmination of a series of pivotal randomised trials of cytotoxic and legend targeted therapies has seen denoting improvements in outcome for patients with both early and advanced disease. This series of articles by primary clinical researchers go into these advances in different areas of breast cancer management.
Resident macrophages influence stem cell activity in the mammary gland
IntroductionMacrophages in the mammary gland are essential for morphogenesis of the ductal epithelial tree and hog been implicated in promoting breast tumor metastasis. Although it is well-established that macrophages drag common mammopoiesis, the mammary cell types that these accessory cells influence retain not been determined. Here we have explored a role for macrophages in regulating mammary stem cell (MaSC) activity, by assessing the dexterity of MaSCs to reconstitute a mammary gland in a macrophage-depleted fat pad. Methods: Two colorful in vivo models were used to deplete macrophages from the mouse mammary fat pad, allowing us to inspect the effect of macrophage deficiency on the mammary repopulating activity of MaSCs.
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
IntroductionTreatment of breast cancer is fitting more individualized with the recognition of tumour subgroups that respond differently to available therapies. Breast cancer 1 gene (BRCA1)-deficient tumors are normally of the basal subtype and associated with destitute survival rates, highlighting the desideratum for amassed effective therapy. Methods: We investigated a mouse pattern that closely mimics breast cancer arising in BRCA1-mutation carriers to exceeding understand the molecular mechanism of tumor order and tested if targeting of the Polycomb-group protein EZH2 would be a putative therapy for BRCA1-deficient tumors. Results: Gene expression discussion demonstrated that EZH2 is overexpressed in BRCA1-deficient mouse mammary tumors.
An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancer
IntroductionPerhaps the chief trial in developing bounteous effective therapeutic strategies for the treatment of breast cancer patients is confronting the heterogeneity of the disease, recognizing that breast cancer is not one disease nevertheless multiple disorders with distinct underlying mechanisms. Gene-expression profiling studies compass been used to dissect this complexity, and our previous studies identified a series of intrinsic subtypes of breast cancer that define many populations of patients with appreciation to survival. Additional assignment has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as able-bodied as to suggest therapeutic opportunities linked to course of action activation.
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by reverse-transcriptase polymerase chain reaction and comparison to status of bone marrow disseminated cells
IntroductionThe role of circulating tumor cells (CTC) in blood of primary breast cancer patients is much under investigation. We evaluated (1) the incidence of CTC in blood, (2) the correlation between CTC and disseminated tumor cells (DTC) in the bone marrow (BM) and (3) we characterized CTC for the expression of HER2, the estrogen receptor (ER) and the progesterone receptor (PR). Methods: Blood of 431 patients with meaningful breast cancer were analysed for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany). Expression of the ER and PR receptor was assessed in an supplementary reverse-transcriptase polymerase chain reaction (RT-PCR).
Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis
IntroductionSites of chronic inflammation are much associated with the establishment and flowering of various malignancies including breast cancer. A common inflammatory context in general public is autoimmune arthritis (AA) that causes inflammation and deformity of the joints. Other systemic effects associated with arthritis include increased cellular infiltration and inflammation of the lungs. Diverse studies accept reported statistically meaningful risk ratios between AA and breast cancer. In spite of this knowledge, available for a decade, it has never been questioned whether the location of chronic inflammation linked to AA creates a milieu that attracts tumor cells to homey and dilate in the inflamed bones and lungs which are frequent sites of breast cancer metastasis.
